Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL3257080 | 0.96 | MEN1 (0.45) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL4945497 | 0.96 | MEN1 (0.43) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL6623892 | 0.95 | MEN1 (0.41) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL18104019 | 0.93 | MEN1 (0.49) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL6697326 | 0.93 | MEN1 (0.49) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL7705890 | 0.93 | MEN1 (0.42) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL168983 | 0.92 | MEN1 (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL18104043 | 0.92 | MEN1 (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL1273606 | 0.92 | MEN1 (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL2533342 | 0.90 | MAPT (0.40) | MEN1MAPTKMT2AATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024101336-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | 国立大学法人京都大学 | 2024-05-16 | — | — | WO | disclosed |
| CN-118020026-A | Photosensitive resin composition, cured product, partition wall, organic electroluminescent element, and image display device | 三菱化学株式会社 | 2024-05-10 | — | — | CN | disclosed |
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2023-12-05 | — | — | US | disclosed |
| CN-111741948-B | Saturated ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | 日本烟草产业株式会社 | 2023-11-10 | — | — | CN | disclosed |
| EP-3760619-B1 | SATURATED RING-CONDENSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUND, AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2023-10-25 | — | — | EP | disclosed |
| US-11793821-B2 | Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME LLC (US) | 2023-10-24 | — | — | US | disclosed |
| CN-116806326-A | Photosensitive resin composition, cured product, partition wall, organic electroluminescent element, color filter, and image display device | 三菱化学株式会社 | 2023-09-26 | — | — | CN | disclosed |
| WO-2023120634-A1 | LAMINATED FILM AND FILM LAMINATE | 三菱ケミカル株式会社 | 2023-06-29 | — | — | WO | disclosed |
| CN-110475785-B | Peptide compound, method for producing same, composition for screening, and method for selecting peptide compound | 富士胶片株式会社 | 2023-06-13 | — | — | CN | disclosed |
| WO-2023054597-A1 | PHOTOSENSITIVE RESIN COMPOSITION, CURED PRODUCT, PARTITION WALL, ORGANIC ELECTROLUMINESCENT ELEMENT, AND IMAGE DISPLAY DEVICE | 三菱ケミカル株式会社 | 2023-04-06 | — | — | WO | disclosed |
| CN-1268947-A | Novel process for preparing 4-hydroxy-2-oxo-pyran derivatives as protease inhibitors | UPJOHN CO (US) | 2000-10-04 | — | — | CN | disclosed |
| US-6127369-A | 5,10-dihydrodipyrido[2,3-b:2,3-e]pyrazin and 5,10-dihydrodipyrido[2,3-b:3,2-e]pyrazin compounds | ADIR ET COMPAGNIE (FR) | 2000-10-03 | — | — | US | disclosed |
| EP-1006113-A1 | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth | Pfizer Products Inc. (US) | 2000-06-07 | — | — | EP | disclosed |
| EP-0812839-A1 | Irreversible HIV protease inhibitors, compositions containing same and process for the preparation thereof | LG Chemical Limited (KR) | 1997-12-17 | — | — | EP | disclosed |
| US-5696134-A | Irreversible HIV protease inhibitors, intermediates, compositions and processes for the preparation thereof | LG CHEMICAL LIMITED (KR) | 1997-12-09 | — | — | US | disclosed |
| US-5670517-A | MULTISTAGE SYNTHESIS WITH EPOXIDATION, DECARBONYLATION, COUPLING BY AMIDATION THEN DECARBONYLATION | LG CHEMICAL LIMITED (KR) | 1997-09-23 | — | — | US | disclosed |
| WO-1997021664-A1 | NAPHTHYL ACETAMIDES AS sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1997-06-19 | — | — | WO | disclosed |
| EP-0779271-A1 | Naphthyl acetamides as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1997-06-18 | — | — | EP | disclosed |
| EP-0687675-A2 | Irreversible HIV protease inhibitors, intermediates, compositions and processes for the preparation thereof | LG Chemical Limited (KR) | 1995-12-20 | — | — | EP | disclosed |
| EP-0396065-A1 | Novel amino acid derivatives possessing renin-inhibitory activities | Japan Tobacco Inc. (JP) | 1990-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | RORC, RORB, RORA | MEN1 3985/4885MAPT 1809/4885KMT2A 1904/4885 |
| US-11793821-B2 | Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors | CHRNA7, CHRNA6, CHRNA5 | MEN1 4885/4885MAPT 379/4885KMT2A 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.